Investigating miR-155 in Migraine Types
Expression of miR-155 in Migraine: Association With Different Phenotypes and Disease Severity
This study is trying to see if a specific molecule in the blood can help doctors better understand and treat different types of migraines.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 90 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | IRCCS National Neurological Institute "C. Mondino" Foundation Academic / other |
| Locations | 1 site (Pavia) |
| Trial ID | NCT05891808 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the expression of microRNA-155 in individuals with episodic and chronic migraine. By analyzing peripheral blood mononuclear cells and monocytes, the research seeks to identify potential biomarkers that could improve diagnosis, predict treatment responses, and assess the risk of chronic migraine development. The study will involve healthy controls and patients diagnosed with episodic migraine, focusing on their miRNA profiles to better understand the neurobiological aspects of migraine. The findings could lead to advancements in migraine management and treatment strategies.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 to 65 with a diagnosis of episodic migraine who have maintained a headache diary for at least three months.
Not a fit: Patients with chronic migraine or other primary and secondary headache disorders may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to the identification of reliable biomarkers for migraine, improving diagnosis and treatment options for patients.
How similar studies have performed: Other studies have shown promise in identifying miRNA signatures in migraine, but this specific focus on miR-155 is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Healthy Controls: Inclusion Criteria: 1. age between \>18 and \<65 years, of both genders Exclusion criteria: 1. diagnosis of primary and/or secondary headache according to ICHD-III criteria (only diagnosis of sporadic tension type headache is allowed) 2. diagnosis of neurological disorders 3. diagnosis of medical conditions considered clinically relevant by the researcher 4. pregnant and lactating women 5. taking NSAIDs, triptans or opiates in the previous 24 hours Episodic Migraine Inclusion Criteria: 1. diagnosis of migraine without or with aura according to ICHD-III criteria 2. age between \>18 and \<65 years of both genders 3. have completed a headache diary for at least 3 months at the time of enrollment Exclusion criteria: 1. history of chronic migraine or other chronic headache subtypes according to ICHD-III criteria 2. concomitant diagnosis of other primary and/or secondary headache according to ICHD-III criteria (only diagnosis of sporadic tension headache is allowed) 3. diagnosis of other neurological disorders 4. diagnosis of medical conditions considered clinically relevant by the researcher 5. diagnosis of chronic pain syndrome of any nature 6. pregnant and lactating women 7. use of substances of abuse 8. taking NSAIDs, triptans or opiates in the previous 24 hours Chronic Migraine Inclusion Criteria: 1. diagnosis of chronic migraine with or without concomitant diagnosis of medication overuse headache according to ICHD-III criteria 2. history of chronic migraine for at least 1 year 3. age between \>18 and \<65 years, of both sexes 4. have completed a headache diary for at least 3 months at the time of enrollment Exclusion criteria: 1. concomitant diagnosis of other primary and/or secondary headache according to ICHD-III criteria (only diagnosis of sporadic tension headache is allowed) 2. concomitant diagnosis of other neurological disorders 3. diagnosis of medical conditions considered clinically relevant by the researcher 4. diagnosis of chronic pain syndrome of any nature 5. pregnant and lactating women 6. use of substances of abuse 7. taking NSAIDs, triptans or opiates within the previous 24 hours
Where this trial is running
Pavia
- IRCCS Mondino Foundation — Pavia, Italy (Recruiting)
Study contacts
- Study coordinator: Roberto De Icco, MD, PhD
- Email: roberto.deicco@mondino.it
- Phone: 00390382380387
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.